Macimorelin Aeterna Zentaris

macimorelin

Opinion

On 15 November 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Macimorelin Aeterna Zentaris intended for the diagnosis of growth hormone deficiency in adults. The applicant for this medicinal product is Aeterna Zentaris GmbH.

Macimorelin Aeterna Zentaris will be available as 60 mg granules for oral solution. The active substance of Macimorelin Aeterna Zentaris is macimorelin, a peptide mimetic with growth hormone secretagogue activity similar to ghrelin (ATC code: V04CD06). Macimorelin stimulates growth hormone release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus.

The benefit with Macimorelin Aeterna Zentaris is its ability to confirm diagnosis of growth hormone deficiency with high sensitivity and specificity in adult patients. The most common side effects are dysgeusia, dizziness, headache, fatigue, feeling hot, nausea and diarrhoea.

"This medicinal product is for diagnostic use only.

Macimorelin Aeterna Zentaris is indicated for the diagnosis of growth hormone deficiency (GHD) in adults (see section 5.1)."

It is proposed that the use of Macimorelin Aeterna Zentaris be supervised by a physician or healthcare professional experienced in diagnosing growth hormone deficiency

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Key facts

Name
Macimorelin Aeterna Zentaris
Agency product number
EMEA/H/C/004660
International non-proprietary name (INN) or common name
  • macimorelin
Active substance
  • macimorelin acetate
Therapeutic area
Diagnostic Techniques, Endocrine
Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Date opinion adopted
15/11/2018
Company name
Aeterna Zentaris GmbH
Status
Positive
Application type
Initial authorisation

How useful was this page?

Add your rating
Average
3 ratings